Global Microbiome Therapeutics Market Size study & Forecast, by Type (FMT, Microbiome Drugs), By Application (C. difficile, Crohn's Disease, Inflammatory Bowel Disease, Diabetes, Others) and Regional Analysis, 2022-2029

Global Microbiome Therapeutics Market Size study & Forecast, by Type (FMT, Microbiome Drugs), By Application (C. difficile, Crohn's Disease, Inflammatory Bowel Disease, Diabetes, Others) and Regional Analysis, 2022-2029

Global Microbiome Therapeutics Market is valued approximately at USD 92.15 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 35.32% over the forecast period 2022-2029. Microbiome treatments aim to engineer the gut microbiome by applying native or synthetic bacteria, antibiotics, bacteriophages, and bacteriocins in additive, subtractive, or modulatory therapy. The market is expanding as a result of factors including the rise in strategic partnerships for R&D, product development, and portfolio expansion in the field of microbiome therapies. Most of the therapeutic drugs in development are still in their early stages, typically between Phase I and Phase II. Out of the 23, more than 13 medicines are being studied for GI indications, with the majority focusing on ulcerative colitis. For instance, Seres Therapeutics, Inc. disclosed SER-109 trial results from its Phase 3 ECOSPOR III study in 2021. It is planned to introduce the pipeline medicine in the first half of 2023 as an oral treatment for recurrent C. difficile infection. SER-109 is connected to a decrease in antimicrobial resistance genes as opposed to placebo. Also, a 4-year partnership for the development and discovery of microbial medicines was established in January 2022 between Hudson Institute and BiomeBank.

The demand for microbiome therapies is also rising as target diseases are becoming more prevalent. The development of microbiome research is anticipated to hunt for more effective cures for infections and other ailments, improving the results of medical therapy. Companies are bringing down the cost of their goods, increasing access to cutting-edge healthcare for a greater percentage of the population, and some countries' governing authorities are changing their strategies to support the adoption of microbiome-based treatments. As a result, this offers market vendors lucrative growth opportunities to increase their market share. The high cost of microbiome treatments and strict regulatory rules brought on by the product's complexity are the two main issues limiting the market's expansion.

The key regions considered for the Global Microbiome Therapeutics Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. With the biggest market share in 2021, North America dominated the industry. The region's dominance is mostly due to its well-established research capabilities for the creation of innovative treatments and its expanding target population. Also, the ubiquity of initiatives like the Canadian Microbiome Initiative (CMI) in Canada makes it easier to work with partners and stakeholders. This makes it possible to concentrate research efforts on the creation of microbial medicines. For instance, the Biocodex Microbiota Foundation published a call for submissions in July 2021 for microbiome research funding totaling more than USD 26,000 in Canada. These incentives are anticipated to stimulate new market innovations. Asia Pacific is predicted to grow significantly during the forecast period, owing to factors such as rising geriatric and target populations, an increase in the number of collaborations for biosimilar development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.

Major market player included in this report are:
OpenBiome
Seres Therapeutics Inc.
4D Pharma plc.
Locus Biosciences, Inc.
Enterome SA
Finch Therapeutics Group, Inc.
Intralytix, Inc.
Microbiotica
Second Genome
Rebiotix Inc.
Recent Developments in the Market:
In December 2021, Kaleido Biosciences and Janssen have joined forces to explore the possibility of microbiome metabolic medicines for the treatment of immunological, atopic, and metabolic diseases that first appear in childhood.
in July 2021, The Biocodex Microbiota Foundation published a request for submissions for microbiome research funding totalling more than USD 26,000 in Canada. These incentives are anticipated to stimulate new market innovations.
Global Microbiome Therapeutics Market Report Scope:

Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Type, Application, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Type:
FMT
Microbiome Drugs

By Application:
C. difficile
Crohn's Disease
Inflammatory Bowel Disease
Diabetes
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Companies Mentioned

OpenBiome
Seres Therapeutics Inc.
4D Pharma plc.
Locus Biosciences, Inc.
Enterome SA
Finch Therapeutics Group, Inc.
Intralytix, Inc.
Microbiotica
Second Genome
Rebiotix Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.